Latest Cancer News

Read the latest cancer news from the National Cancer Institute. The UNM Comprehensive Cancer Center is one of only 49 NCI-designated comprehensive cancer centers bringing leading, national cancer care to New Mexico.

CCDI Activities Enhance NCI’s Childhood and AYA Cancer Research


Since launching the Childhood Cancer Data Initiative, NCI has undertaken a range of research activities to support this important effort. In this Cancer Currents post, NCI Director Dr. Norman Sharpless provides an update on these efforts.

Study Links Mental Health Treatment to Improved Cancer Survival


In a study of more than 50,000 veterans with lung cancer, those with mental illness who received mental health treatment—including for substance use—lived substantially longer than those who didn’t participate in such programs.

A New FDA Approval Furthers the Role of Genomics in Cancer Care


FDA’s approval of pembrolizumab (Keytruda) to treat people whose cancer is tumor mutational burden-high highlights the importance of genomic testing to guide treatment, including for children with cancer, according to NCI Director Dr. Ned Sharpless.

New Drug Regimen Cures More Children with Aggressive B-Cell Lymphoma


For children with aggressive Burkitt lymphoma and other B-cell non-Hodgkin lymphomas, adding rituximab (Rituxan, Truxima) to chemotherapy substantially increases the likelihood of the child being cured, results from a large clinical trial show.

Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials


In response to the COVID-19 pandemic, cancer researchers are making changes to clinical trials to ensure patient safety and protect the integrity of their work. Some changes, such as greater use of telemedicine, will likely continue into the future.

New on NCI’s Websites for June 2020


NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of June 2020.

Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer


Results from a large study show that, for most people with advanced bladder cancer, starting immunotherapy with avelumab (Bavencio) shortly after initial treatment with chemotherapy is better than delaying treatment.

Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations


FDA has granted accelerated approval for selpercatinib (Retevmo) to treat certain patients with thyroid cancer or non-small cell lung cancer whose tumors have RET gene alterations. The drug, which works by blocking the activity of RET proteins, was approved based on the results of the LIBRETTO-001 trial.

Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer


Many advanced cancer patients suffer from chronic nausea and vomiting and there aren’t many good treatments available. But a small study suggests that the drug olanzapine (Zyprexa) may fill that gap.

With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era


FDA has approved olaparib (Lynparza) and rucaparib (Rubraca) to treat some men with metastatic prostate cancer. The PARP inhibitors are approved for men whose cancers have stopped responding to hormone treatment and have specific genetic alterations.